[{"address1": "234 Church Street", "address2": "Suite 1020", "city": "New Haven", "state": "CT", "zip": "06510", "country": "United States", "phone": "203 859 3820", "website": "https://www.rallybio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.", "fullTimeEmployees": 43, "companyOfficers": [{"maxAge": 1, "name": "Dr. Martin W. MacKay Ph.D.", "age": 67, "title": "Co-Founder & Executive Chairman", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 723350, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen  Uden M.B, M.D.", "age": 65, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 723350, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan I. Lieber M.B.A.", "age": 53, "title": "CFO & Treasurer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 667134, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 8, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.8, "open": 1.76, "dayLow": 1.7, "dayHigh": 1.8, "regularMarketPreviousClose": 1.8, "regularMarketOpen": 1.76, "regularMarketDayLow": 1.7, "regularMarketDayHigh": 1.8, "beta": -1.641, "forwardPE": -1.2222222, "volume": 512628, "regularMarketVolume": 512628, "averageVolume": 1636825, "averageVolume10days": 8947170, "averageDailyVolume10Day": 8947170, "bid": 1.72, "ask": 1.79, "bidSize": 100, "askSize": 100, "marketCap": 72949008, "fiftyTwoWeekLow": 1.225, "fiftyTwoWeekHigh": 9.14, "fiftyDayAverage": 1.7994, "twoHundredDayAverage": 3.318525, "currency": "USD", "enterpriseValue": -42987932, "floatShares": 21165628, "sharesOutstanding": 41448300, "sharesShort": 1310415, "sharesShortPriorMonth": 1198693, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0347, "heldPercentInsiders": 0.056160003, "heldPercentInstitutions": 0.87176, "shortRatio": 8.89, "shortPercentOfFloat": 0.041199997, "impliedSharesOutstanding": 41448300, "bookValue": 2.807, "priceToBook": 0.6270039, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -74564000, "trailingEps": -1.84, "forwardEps": -1.44, "enterpriseToEbitda": 0.546, "52WeekChange": -0.6036036, "SandP52WeekChange": 0.2160933, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "RLYB", "underlyingSymbol": "RLYB", "shortName": "Rallybio Corporation", "longName": "Rallybio Corporation", "firstTradeDateEpochUtc": 1627565400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "49dd8bea-3b9a-369d-b66d-d25eaa1b0182", "messageBoardId": "finmb_1673028342", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.76, "targetHighPrice": 20.0, "targetLowPrice": 8.0, "targetMeanPrice": 12.6, "targetMedianPrice": 11.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 109929000, "totalCashPerShare": 2.907, "ebitda": -78782000, "totalDebt": 392000, "quickRatio": 11.868, "currentRatio": 12.392, "debtToEquity": 0.369, "returnOnAssets": -0.33326998, "returnOnEquity": -0.5413, "freeCashflow": -34151500, "operatingCashflow": -60265000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-18"}]